See more : Startia Holdings,Inc. (3393.T) Income Statement Analysis – Financial Results
Complete financial analysis of Beam Therapeutics Inc. (BEAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beam Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Formosan Union Chemical Corp. (1709.TW) Income Statement Analysis – Financial Results
- Guanfu Holding Co., Ltd. (002102.SZ) Income Statement Analysis – Financial Results
- Arch Capital Group Ltd. (ACGLO) Income Statement Analysis – Financial Results
- Rex Sealing and Packing Indust (REXSEAL.BO) Income Statement Analysis – Financial Results
- OUTLOOKCONSULTING CO LTD (5596.T) Income Statement Analysis – Financial Results
Beam Therapeutics Inc. (BEAM)
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 377.71M | 60.92M | 51.84M | 24.00K | 18.00K | 0.00 | 0.00 |
| Cost of Revenue | 437.38M | 22.58M | 16.44M | 103.18M | 5.41M | 650.00K | 11.00K |
| Gross Profit | -59.67M | 38.34M | 35.40M | -103.16M | -5.39M | -650.00K | -11.00K |
| Gross Profit Ratio | -15.80% | 62.94% | 68.29% | -429,812.50% | -29,938.89% | 0.00% | 0.00% |
| Research & Development | 437.38M | 311.59M | 387.09M | 103.18M | 54.62M | 33.87M | 5.86M |
| General & Administrative | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -71.00K | -10.04M | 378.00K |
| Operating Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Cost & Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Interest Income | 0.00 | 15.30M | 9.00K | 1.57M | 2.49M | 292.00K | 0.00 |
| Interest Expense | 0.00 | 15.30M | 9.00K | 1.57M | 187.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 20.01M | 22.58M | 16.44M | 9.47M | 5.41M | 650.00K | 11.00K |
| EBITDA | -156.47M | -324.33M | -392.47M | -128.03M | -71.65M | -45.09M | -7.99M |
| EBITDA Ratio | -41.43% | -659.03% | -799.13% | -269,270.83% | -384,644.44% | 0.00% | 0.00% |
| Operating Income | -176.49M | -338.48M | -392.47M | -132.76M | -75.15M | -45.74M | -7.88M |
| Operating Income Ratio | -46.73% | -555.61% | -757.01% | -553,166.67% | -417,522.22% | 0.00% | 0.00% |
| Total Other Income/Expenses | 45.32M | 78.30M | 21.83M | -61.83M | -3.17M | -71.00M | -122.00K |
| Income Before Tax | -131.16M | -260.18M | -370.64M | -194.59M | -78.33M | -116.74M | -8.00M |
| Income Before Tax Ratio | -34.73% | -427.08% | -714.91% | -810,800.00% | -435,144.44% | 0.00% | 0.00% |
| Income Tax Expense | 1.37M | 3.41M | -29.28M | 61.83M | 116.00K | -71.00M | 500.00K |
| Net Income | -132.53M | -263.59M | -341.36M | -256.42M | -78.44M | -115.26M | -8.00M |
| Net Income Ratio | -35.09% | -432.68% | -658.44% | -1,068,433.33% | -435,788.89% | 0.00% | 0.00% |
| EPS | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| EPS Diluted | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| Weighted Avg Shares Out | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
| Weighted Avg Shares Out (Dil) | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
National Bank of Canada FI Grows Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
DESERT MOUNTAIN ENERGY ANNOUNCES STRATEGIC PARTNERSHIP WITH BEAM EARTH LTD. FOR HYDROGEN IN ARIZONA AND NEW MEXICO
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Source: https://incomestatements.info
Category: Stock Reports